Biggest changeReconciliation of Net Loss to Adjusted EBITDA Year Ended December 31, (In thousands) 2023 2022 Net Loss $ (134,098) $ (76,356) Depreciation 5,452 4,660 Interest income, net (4,572) (8) Stock-based compensation expense and change in fair value of SAFE and warrant liabilities (1) 728 4,476 Change in fair value of the FPA Put Option and Fixed Maturity Consideration liabilities 44,300 — Transaction costs on issuance of Forward Purchase Agreement 451 — Loss (gain) from equity method investees, net 2,902 (1,992) One-time costs related to the Business Combination, initial securities registration and non-recurring regulatory matters (2) 4,693 — Adjusted EBITDA $ (80,144) $ (69,220) __________________ (1) Stock-based compensation expense represents expense related to equity compensation plans (2) Represents costs incurred related to the Business Combination that do not meet the direct and incremental criteria per SEC Staff Accounting Bulletin Topic 5.A to be charged against the gross proceeds of the transaction, but are not expected to recur in the future, as well as costs incurred subsequent to deal close related to our securities registration on Form S-4 and our registration statement on Form S-1.Regulatory matters includes fees related to non-recurring items during the year ended December 31, 2023.
Biggest changeThe following table reconciles Adjusted EBITDA to net loss, the most directly comparable financial measure calculated and presented in accordance with GAAP: Reconciliation of Net Loss to Adjusted EBITDA Years Ended December 31, (In thousands) 2024 2023 Net Loss $ (137,731) $ (134,098) Depreciation 5,567 5,452 Interest income, net (3,162) (4,572) Stock-based compensation expense and change in fair value of SAFE and warrant liabilities (1) (4,679) 728 Change in fair value of the FPA Put Option and Fixed Maturity Consideration liabilities (net of interest accretion reversal) 23,283 44,300 Change in fair value of Convertible Note and related transaction costs 14,276 — Transaction costs on issuance of FPA — 451 Loss from equity method investees, net 14,234 2,902 One-time costs related to the Business Combination, initial securities registration and non-recurring regulatory matters (2) — 4,693 Adjusted EBITDA $ (88,212) $ (80,144) __________________ (1) Stock-based compensation expense represents expense related to equity compensation plans.
For example, adjusted EBITDA: (i) excludes stock-based compensation expense because it is a significant non-cash expense that is not directly related to our operating performance; (ii) excludes depreciation expense and, although this is a non-cash expense, the assets being depreciated and amortized may have to be replaced in the future; (iii) excludes gain or losses on equity method investee; and (iv) excludes certain income or expense items that do not provide a comparable measure of our business performance.
For example, Adjusted EBITDA: (i) excludes stock-based compensation expense because it is a significant non-cash expense that is not directly related to our operating performance; (ii) excludes depreciation expense and, although this is a non-cash expense, the assets being depreciated and amortized 71 may have to be replaced in the future; (iii) excludes gain or losses on equity method investee; and (iv) excludes certain income or expense items that do not provide a comparable measure of our business performance.
The Company also has certain partnership agreements that are within the scope of ASC 808 and contract with governmental entities that are accounted for as grant contributions. We primarily earn revenue from services related to feasibility studies and basic engineering design of commercial plants, joint development, and contract R&D activities to develop novel biocatalysts and related technologies.
The Company also has certain partnership agreements that are within the scope of ASC 808 and contracts with governmental entities that are accounted for as grant contributions. We primarily earn revenue from services related to feasibility studies and basic engineering design of commercial plants, joint development, and contract R&D activities to develop novel biocatalysts and related technologies.
Non-GAAP Financial Measures To supplement our financial statements presented in accordance with US GAAP and to provide investors with additional information regarding our financial results, we have presented adjusted EBITDA, a non-GAAP financial measure. Adjusted EBITDA is not based on any standardized methodology prescribed by US GAAP and is not necessarily comparable to similarly titled measures presented by other companies.
Non-GAAP Financial Measures To supplement our financial statements presented in accordance with GAAP and to provide investors with additional information regarding our financial results, we have presented Adjusted EBITDA, a non-GAAP financial measure. Adjusted EBITDA is not based on any standardized methodology prescribed by GAAP and is not necessarily comparable to similarly titled measures presented by other companies.
While our significant accounting policies are more fully described in Note 2 to our consolidated financial statements, we believe that the accounting policies discussed below are critical to understanding our historical and future performance: Revenue Recognition We recognize revenue from our contracts with customers in accordance with ASC 606.
While our significant accounting policies are more fully described in Note 2 to our consolidated financial statements, we believe that the accounting policies discussed below are critical to understanding our historical and future performance: Revenue Recognition 69 We recognize revenue from our contracts with customers in accordance with ASC 606.
Adjusted EBITDA is a supplemental measure that is not a substitute for, or superior to, measures of financial performance prepared in accordance with US GAAP. Adjusted EBITDA does not represent, and should not be considered, an alternative to net income (loss), as determined in accordance with US GAAP.
Adjusted EBITDA is a supplemental measure that is not a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP. Adjusted EBITDA does not represent, and should not be considered, an alternative to net income (loss), as determined in accordance with GAAP.
Off-Balance Sheet Arrangements As of December 31, 2023 and December 31, 2022, we did not engage in any off-balance sheet arrangements, including the use of structured finance, special purpose entities or variable interest entities.
Off-Balance Sheet Arrangements As of December 31, 2024 and December 31, 2023, we did not engage in any off-balance sheet arrangements, including the use of structured finance, special purpose entities or variable interest entities.
(2) Consists of cost of revenues from contracts with customers and grants (exclusive of depreciation), cost of revenue from collaboration agreements (exclusive of depreciation) and cost of revenue from related party transactions (exclusive of depreciation).
(3) Consists of cost of revenues from contracts with customers and grants (exclusive of depreciation), cost of revenue from collaboration agreements (exclusive of depreciation) and cost of revenue from related party transactions (exclusive of depreciation).
We determined this by evaluating the pipeline of potential Brookfield projects in various stages of development, and determining the likelihood that a sufficient number of projects should meet the criteria for investment prior to maturity of the note.
We determined the value of the conversion portion, by evaluating the pipeline of potential Brookfield projects in various stages of development, and determining the likelihood that a sufficient number of projects should meet the criteria for investment prior to maturity of the note.
(3) Adjusted EBITDA, a non-GAAP financial measure, is calculated as net loss, excluding the impact of depreciation, interest income, net, stock-based compensation, change in fair value of warrant liabilities, change in fair value of SAFE liabilities, change in fair value of the FPA Put Option liability and Fixed Maturity Consideration, transaction costs on issuance of Forward Purchase Agreement, (loss) gain from equity method investees and other one-time costs related to the Business Combination and securities registration on Form S-4 and our registration statement on Form S-1.
(4) Adjusted EBITDA, a non-GAAP financial measure, is calculated as net loss, excluding the impact of depreciation, interest income, net, stock-based compensation, change in fair value of warrant liabilities, change in fair value of SAFE liabilities, change in fair value of the FPA Put Option liability and Fixed Maturity Consideration, change in fair value of the Convertible Note and associated transaction costs, transaction costs on issuance of FPA, loss from equity method investees, net and other one-time costs related to the Business Combination and securities registration on Form S-4, our registration statement on Form S-1, and non-recurring regulatory matters.
We define adjusted EBITDA as our net loss, excluding the impact of depreciation, interest income, net, stock-based compensation, change in fair value of warrant liabilities, change in fair value of SAFE liabilities, change in fair value of the FPA Put Option liability and Fixed Maturity Consideration, transaction costs on issuance of Forward Purchase Agreement, (loss) gain from equity method investees and other one-time costs related to the Business Combination and securities registration on Form S-4 and our registration statement on Form S-1.
We define Adjusted EBITDA as our net loss, excluding the impact of depreciation, interest income, net, stock-based compensation, change in fair value of warrant liabilities, change in fair value of SAFE liabilities, change in fair value of the FPA Put Option liability and Fixed Maturity Consideration, change in fair value of the Convertible Note and associated transaction costs, transaction costs on issuance of FPA, loss from equity method investees, net and other one-time costs related to the Business Combination and securities registration on Form S-4, our registration statement on Form S-1, and non-recurring regulatory matters.
In the normal course of our business, we also enter into purchase commitments or other transactions in which we make representations and warranties that relate to the performance of our goods and services. We do not expect material losses related to these transactions.
In the normal course of our business, we also enter into purchase commitments or other transactions in which we make representations and warranties that relate to the performance of our goods and services. We do not expect material losses related to these transactions. Going Concern We have recurring net losses and anticipate continuing to incur losses.
In 2018, through our joint venture with Shougang LanzaTech (also referred as “SGLT” herein), we established the world’s first commercial waste gas-to-ethanol plant in China, followed by five more plants between 2021 and 2023 - three in China, one in India, and one in Belgium with others currently in development in various countries around the world.
In 2018, through our joint venture with Shougang LanzaTech (also referred as “SGLT” herein), we established the world’s first commercial waste gas-to-ethanol plant in China, followed by three more plants between 2021 and 2023.
There are a number of limitations related to the use of adjusted EBITDA rather than net loss, which is the most directly comparable financial measure calculated and presented in accordance with US GAAP.
Adjusted EBITDA is not prepared in accordance with GAAP and should not be considered in isolation of, or as an alternative to, measures prepared in accordance with GAAP. There are a number of limitations related to the use of Adjusted EBITDA rather than net loss, which is the most directly comparable financial measure calculated and presented in accordance with GAAP.
Basis of Presentation LanzaTech’s consolidated financial statements were prepared in accordance with US GAAP. See Note 2 - Summary of Significant Accounting Policies to our consolidated financial statements for a full description of our basis of presentation.
See Note 2 - Summary of Significant Accounting Policies to our consolidated financial statements for a full description of our basis of presentation.
Pursuant to the Forward Purchase Agreement, ACM obtained 5,916,514 shares of common stock on the open market for $10.16 per share (“Redemption Price”), and such purchase price of $60.1 million was funded by the use of Trust Account proceeds as a partial prepayment (“Prepayment Amount”) for the Forward Purchase Agreement redemption at the end of three years (“Maturity Date”).
Pursuant to the FPA, the Purchasers obtained 5,916,514 shares of common stock (the “Recycled Shares”) on the open market for approximately $10.16 per share (the “Redemption Price”), and the purchase price of approximately $60.1 million was funded by the use of AMCI trust account proceeds as a partial prepayment (the “Prepayment Amount”) for the FPA redemption three years from the date of the Business Combination (the “FPA Maturity Date”).
LanzaTech does not have any outstanding debt, other than the Brookfield SAFE and the FPA Put Option Liability and Fixed Maturity Consideration, which are all classified as liabilities for accounting purposes, on its consolidated balance sheets as of December 31, 2023.
As of December 31, 2024, LanzaTech’s outstanding debt comprised the Convertible Note, the Brookfield SAFE, the FPA Put Option liability and the Fixed Maturity Consideration, which are all classified as liabilities for accounting purposes, on its consolidated balance sheets as of December 31, 2024.
On February 8, 2023, Merger Sub merged with and into LanzaTech NZ, Inc. Upon consummation of the Business Combination, the separate corporate existence of Merger Sub ceased, and LanzaTech NZ, Inc. survived the Business Combination and became a wholly owned subsidiary of AMCI. In connection with the consummation of the Business Combination, the combined company was renamed “LanzaTech Global, Inc.”.
Upon consummation of the Business Combination, the separate corporate existence of Merger Sub ceased, and LanzaTech NZ, Inc. survived the Business Combination and became a wholly owned subsidiary of AMCI. In connection with the consummation of the Business Combination, the combined Company was renamed “LanzaTech Global, Inc.” Basis of Presentation LanzaTech’s consolidated financial statements were prepared in accordance with GAAP.
Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations The following discussion and analysis should be read in conjunction with our consolidated financial statements and the related notes included in Part II, Item 8 of this Annual Report, and our audited consolidated financial statements.
Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations The following discussion and analysis should be read in conjunction with the consolidated financial statements and accompanying footnotes thereto included in Part II, “Item 8-Financial Results and Supplementary Data” of this Annual Report on Form 10-K.
Filing Status The market value of LanzaTech’s common stock that was held by non-affiliates (i.e. public float) exceeded $700 million as of the last business day of the Company’s 2023 second fiscal quarter which resulted in the following changes to LanzaTech’s filing status: • LanzaTech became a large accelerated filer as of 12/31/2023. • LanzaTech lost emerging growth company status as of 12/31/2023. • LanzaTech no longer qualified as an smaller reporting company as of the last business day of the Company’s second fiscal quarter.
Filing Status LanzaTech’s revenue was less than $100 million for the year ended December 31, 2023, and the market value of its common stock that was held by non-affiliates (i.e. public float) did not exceed $560 million as of the last business day of the Company’s second fiscal quarter in 2024, which resulted in the following changes to LanzaTech’s filing status: • LanzaTech is no longer a large accelerated filer and qualified as a non-accelerated filer as of December 31, 2024. • LanzaTech qualified as a smaller reporting company as of the last business day of the Company’s second fiscal quarter.
In addition to the Prepayment Amount and the Maturity Consideration, on the Maturity Date, New LanzaTech will pay to ACM an amount equal to the product of (x) 500,000 and (y) the Redemption Price, totaling $5.1 million (the “Share Consideration”).
In addition to the Maturity Consideration, on the FPA Maturity Date, the Company is obligated to pay the Purchasers an amount equal to the product of (x) 500,000 and (y) the Redemption Price, totaling $5.1 million (the “Share Consideration”), which under the FPA is payable in cash.
The following table shows the balances of our cash, cash equivalents and restricted cash as of December 31, 2023 and December 31, 2022: As of Change (In thousands, except for percentages) December 31, 2023 December 31, 2022 2023 vs. 2022 Total cash, cash equivalents, and restricted cash $ 76,284 $ 83,710 $ (7,426) (9) % As of December 31, 2023, compared to December 31, 2022, LanzaTech’s cash, cash equivalents, and restricted cash decreased by $7.4 million, or 9%, primarily due to the net loss adjusted for non-cash charges (see cash flow section below), the partial prepayment for the FPA, purchases of debt security investments, purchases of property, plant and equipment and the repurchase of equity instruments of the Company.
The following table shows the balances of our cash, cash equivalents and restricted cash as of December 31, 2024 and December 31, 2023: Years Ended December 31, (In thousands, except for percentages) 2024 2023 Variance % Change Total cash, cash equivalents, and restricted cash $ 45,737 $ 76,284 $ (30,547) (40) % As of December 31, 2024, compared to December 31, 2023, LanzaTech’s cash, cash equivalents, and restricted cash decreased by $30.5 million, or 40%, primarily due to funding the net loss adjusted for non-cash charges (see cash flow section below) and purchases of property, plant and equipment.
We have not achieved operating profitability since our formation. Our net losses after tax were $(134.1) million for the year ended December 31, 2023 and $(76.4) million for the year ended December 31, 2022. As of December 31, 2023 we had an accumulated deficit of $(831.9) million compared to an accumulated deficit of $(456.2) million as of December 31, 2022.
Our net losses after tax were $137.7 million for the year ended December 31, 2024 and $134.1 million for the prior year. As of December 31, 2024 we had accumulated deficit of $969.6 million compared to an accumulated deficit of $831.9 million as of December 31, 2023.
In addition, other companies may use other measures to evaluate their performance, all of which could reduce the usefulness of our non-GAAP financial measures as tools for comparison. The following table reconciles adjusted EBITDA to net loss, the most directly comparable financial measure calculated and presented in accordance with US GAAP.
In addition, other companies may use other measures to evaluate their performance, all of which could reduce the usefulness of our non-GAAP financial measures as tools for comparison.
Critical Accounting Policies and Management Estimates Our management’s discussion and analysis of our financial condition and results of operations is based on our consolidated financial statements that have been prepared in accordance with US GAAP.
Critical Accounting Estimates Our management’s discussion and analysis of our financial condition and results of operations is based on our consolidated financial statements that have been prepared in accordance with GAAP. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, and related disclosures.
Selling, General and Administrative Expense SG&A expense increased $23.6 million, or 88%, in the year ended December 31, 2023 compared to the year ended December 31, 2022.
Selling, general and administrative expense SG&A expense decreased $0.5 million, or 1%, in the year ended December 31, 2024, compared to the prior year .
As of December 31, 2023, held-to-maturity security investments totaled $45.2 million. The Company did not have any held-to-maturity security investments as of December 31, 2022. Sources and Uses of Capital Since inception, we have financed our operations primarily through equity and debt financing.
These securities all mature within one year and will provide additional liquidity upon maturity. As of December 31, 2024, held-to-maturity security investments totaled $12.4 million, compared to $45.2 million as of December 31, 2023. Sources and Uses of Capital Since inception, we have financed our operations primarily through equity and debt financing.
We primarily employ a licensing business model whereby our customers build, own and operate facilities that use our technology, and in return, we are paid a royalty fee based on the revenue generated from the use of our technology. We began operations in 2005.
We have also developed the capabilities to produce single cell protein as a primary product from our gas fermentation platform. LanzaTech employs a licensing business model whereby our customers build, own and operate facilities that use our technology, and in return, we are paid a royalty fee based on the revenue generated from the use of our technology.
See “ Non-GAAP Financial Measures ” for additional information and reconciliation of Adjusted EBITDA to net loss, its most directly comparable US GAAP measure.
See “ Non-GAAP Financial Measures ” for additional information and reconciliation of Adjusted EBITDA to net loss, its most directly comparable GAAP measure. 63 Results of Operations The results of operations presented below should be reviewed in conjunction with our consolidated financial statements and notes.
Key Financial Metrics: The key elements of LanzaTech’s performance for the years ended December 31, 2023 and December 31, 2022 are summarized in the tables below: Year Ended December 31, Change (In thousands, except for percentages) 2023 2022 2023 vs. 2022 GAAP Measures: Revenue $ 62,631 $ 37,343 $ 25,288 68 % Net Loss (134,098) $ (76,356) (57,742) 76 % Key Performance Indicators: One-Time Revenue 57,754 33,764 23,990 71 % Recurring Revenue (1) 4,877 3,579 1,298 36 % Total Revenue $ 62,631 $ 37,343 $ 25,288 68 % Cost of Revenues (ex.
Key Financial Metrics: The key elements of LanzaTech’s performance for the years ended December 31, 2024 and December 31, 2023 are summarized in the tables below: Years Ended December 31, (In thousands, except for percentages) 2024 2023 Variance % Change GAAP Measures: Revenue $ 49,592 $ 62,631 $ (13,039) (21) % Net Loss (137,731) (134,098) (3,633) 3 % Key Performance Indicators: One-Time Revenue (1) 37,868 57,754 (19,886) (34) % Recurring Revenue (2) 11,724 4,877 6,847 140 % Total Revenue 49,592 62,631 (13,039) (21) % Cost of Revenues (ex.
The decrease is offset by cash received from the closing of the Business Combination and PIPE financing. Debt Security Investments Debt security investments comprise mainly held-to-maturity U.S. Treasury and high quality corporate securities that the Company has both the ability and intent to hold to maturity. These securities all mature within one year and will provide additional liquidity upon maturity.
The decrease was offset by the proceeds from the maturity of certain debt securities and the issuance of the Convertible Note. 65 Debt Security Investments Debt security investments comprise mainly held-to-maturity U.S. Treasury and high quality corporate securities that the Company has both the ability and intent to hold to maturity.
Cash Flows from Financing Activities For the year ended December 31, 2023, net cash provided by financing activities was $148.2 million. This was driven by $213.4 million in proceeds from the Business Combination and PIPE financing and proceeds of $2.6 million from the exercise of options to acquire shares of common stock of the Company.
Cash Flows from Financing Activities In the year ended December 31, 2024, net cash from financing activities was $30.2 million , compared to net cash provided by financing activities of $148.2 million in the year ended December 31, 2023.
As of December 31, 2023, the Company expects to present sufficient projects to Brookfield to result in the Brookfield SAFE being automatically converted into shares.
As of December 31, 2024, we expected to present projects to Brookfield to result in the Brookfield SAFE liability being automatically converted into shares at 75% with the remaining portion to be outstanding until maturity.
LanzaTech continued to use the scaled disclosures permitted for SRCs through this Form 10-K, and must begin providing non-scaled larger company disclosures in its quarterly report on Form 10-Q for the first quarter of 2024. The use of reduced disclosure obligations in this Form 10-K may also make comparison of LanzaTech’s financial statements with other public companies difficult or impossible.
LanzaTech uses certain scaled disclosures as permitted for smaller reporting companies in this Form 10-K, including presenting only the two most recent fiscal years of audited financial statements. The use of reduced disclosure obligations in this Form 10-K may also make comparison of LanzaTech’s financial statements with other public companies difficult or impossible.
The following table sets forth our consolidated results of operations for the periods indicated: Year Ended December 31, Change 2023 2022 2023 vs. 2022 (In thousands, except for per share amounts) Total revenue 62,631 37,343 25,288 68 % Cost of revenues (exclusive of depreciation shown below) (44,979) (28,287) (16,692) 59 % Operating expenses: Research and development (68,142) (53,191) (14,951) 28 % Depreciation expense (5,452) (4,660) (792) 17 % Selling, general and administrative expense (50,438) (26,804) (23,634) 88 % Total operating expenses $ (124,032) $ (84,655) $ (39,377) 47 % Loss from operations (106,380) (75,599) (30,781) 41 % Interest income, net 4,572 8 4,564 N/M Other expense, net (29,388) (2,757) (26,631) N/M Total other expense, net (24,816) (2,749) (22,067) N/M Loss before income taxes $ (131,196) $ (78,348) $ (52,848) 67 % Income tax benefit — — — N/M (Loss) gain from equity method investees, net (2,902) 1,992 (4,894) (246) % Net loss $ (134,098) $ (76,356) $ (57,742) 76 % Other comprehensive loss: Foreign currency translation adjustments (376) (1,449) 1,073 74 % Comprehensive loss $ (134,474) $ (77,805) $ (56,669) 73 % Net loss per share - basic and diluted (0.79) (12.37) Weighted-average number of common shares outstanding - basic and diluted 176,023,219 9,302,080 Revenue Total revenue increased $25.3 million, or 68%, in the year ended December 31, 2023 compared to the year ended December 31, 2022.
The following table sets forth our consolidated results of operations for the periods indicated: Years Ended December 31, 2024 2023 Variance % Change (In thousands, except for per share amounts) Total revenue $ 49,592 $ 62,631 $ (13,039) (21) % Cost of revenues (exclusive of depreciation shown below) 25,970 44,979 (19,009) (42) % Operating expenses: Research and development 77,007 68,142 8,865 13 % Depreciation expense 5,567 5,452 115 2 % Selling, general and administrative expense 49,981 50,438 (457) (1) % Total operating expenses $ 132,555 $ 124,032 8,523 7 % Loss from operations (108,933) (106,380) (2,553) 2 % Other income (expense): Interest income, net 3,162 4,572 (1,410) (31) % Other expense, net (17,726) (29,388) 11,662 (40) % Total other expense, net (14,564) (24,816) 10,252 (41) % Loss before income taxes (123,497) (131,196) 7,699 (6) % Loss from equity method investees, net (14,234) $ (2,902) (11,332) 390 % Net loss $ (137,731) $ (134,098) $ (3,633) 3 % Other comprehensive loss: Changes in credit risk of fair value instruments (1,096) — (1,096) nm Foreign currency translation adjustments 124 (376) 500 (133) % Comprehensive loss $ (138,703) $ (134,474) $ (4,229) 3 % Net loss per share - basic and diluted $ (0.70) (0.79) Weighted-average number of common shares outstanding - basic and diluted 197,579,945 176,023,219 Revenue Total revenue decreased $13.0 million, or 21%, in the year ended December 31, 2024, compared to the prior year.
Depreciation) (2) (44,979) (28,287) (16,692) 59 % Selling, general & administrative (50,438) (26,804) (23,634) 88 % Adjusted EBITDA (3) $ (80,144) $ (69,220) $ (10,924) 16 % __________________ (1) Includes revenue from licensing and sales of microbes and media.
Depreciation) (3) 25,970 44,979 (19,009) (42) % Selling, general & administrative 49,981 50,438 (457) (1) % Adjusted EBITDA (4) $ (88,212) $ (80,144) $ (8,068) 10 % __________________ (1) One-time revenue includes all other revenue other than licensing and sales of microbes and media (2) Includes revenue from licensing and sales of microbes and media.
Most performance obligations on our non-governmental arrangements are recognized over time. We typically use percentage completion when certain revenue recognition requirements are met. We exercise judgment when determining the percentage of completion against the total transaction price initially estimated.
We regularly reassess our estimates and assumptions and any changes in these estimates are reflected in our revenue from contracts with customers in the period in which they occur. Most performance obligations on our non-governmental arrangements are recognized over time. We typically use percentage completion when certain revenue recognition requirements are met.
For arrangements with government agencies, we measure the satisfaction of performance obligations over time using the input method which requires judgment when selecting the most indicative measure of such performance. Grant Revenue Grants received, including cost reimbursement agreements, are assessed to determine if the agreement should be accounted for as an exchange transaction or a contribution.
We exercise judgment when determining the percentage of completion against the total transaction price initially estimated. For arrangements with government agencies, we measure the satisfaction of performance obligations over time using the input method which requires judgment when selecting the most indicative measure of such performance.
The increase was primarily driven by engineering and other services with an increase of $16.6 million in revenue from contracts with existing customers and governmental entities whose projects have moved to the next phase of development and an increase of $3.6 million from contracts with new customers.
This decrease in engineering was offset by an increase from existing projects of $3.2 million and from projects with new customers of $6.2 million in 2024. The decline in revenue from engineering was offset by an increase in revenue from licensing of $7.8 million and CarbonSmart sales of $2.6 million.
Joint Development and Contract Research We perform R&D services related to novel technologies and the development of biocatalysts for commercial applications, mainly to produce fuels and chemicals. We engage in two main types of R&D services – joint development agreements, and other contract research, including projects with the U.S. Department of Energy.
With additional partnerships, we established two more commercial plants, one in India, and one in Belgium, respectively, and we currently have other plants in various states of development in various countries around the world. We also perform research and development (“R&D”) services related to novel technologies and development of biocatalysts for commercial applications, mainly to produce fuels and chemicals.
At the end of the three-year term, LanzaTech is obligated to pay ACM an amount equal to the product of (1) 7,500,000 less (b) the number of Terminated Shares multiplied by (2) $2.00 (the “Maturity Consideration”).
At the FPA Maturity Date, the Company is obligated to pay the Purchasers an amount equal to the product of (1) 7,500,000 less the number of Terminated Shares multiplied by (2) $2.00 (the “Maturity Consideration”), which under the FPA is payable at the Company’s option in cash or shares of common stock valued at the average daily VWAP Price (as defined in the FPA) over the 30 scheduled trading days ending on the FPA Maturity Date.
Since the liquidity price is not expected to change during the life of the Brookfield SAFE, the number of shares that Brookfield receives is fixed.
Since the liquidity price was not expected to change during the life of the Brookfield SAFE, the number of shares that Brookfield would receive was fixed. With respect to the maturity portion, the Brookfield SAFE would not automatically be converted prior to maturity and at maturity, the holder could either convert or receive the remaining principal and interest in cash.
We anticipate that we will continue to incur losses until we sufficiently commercialize our technology. Near-term, we expect engineering services and sales of equipment packages on several projects to drive higher revenues. The Business Combination On March 8, 2022, AMCI entered into the Merger Agreement with LanzaTech NZ, Inc. and AMCI Merger Sub, Inc. (“Merger Sub”).
The Business Combination On March 8, 2022, AMCI entered into the Merger Agreement with LanzaTech NZ, Inc. and AMCI Merger Sub, Inc. (“Merger Sub”). On February 8, 2023, Merger Sub merged with and into LanzaTech NZ, Inc.
Brookfield SAFE Valuation The Brookfield SAFE was classified as a liability on our consolidated balance sheets as of December 31, 2023 and 2022. The company elected to record the instrument using the fair value option under ASC 825. The Brookfield SAFE was issued on October 2, 2022.
Brookfield SAFE Valuation Under the Brookfield SAFE, we agreed to issue to Brookfield the right to certain shares of Legacy LanzaTech’s capital stock, in exchange for the payment of $50.0 million. The Brookfield SAFE was classified as a liability on our consolidated balance sheets as of December 31, 2024 and 2023.
Interest income, net Interest income, net increased $4.6 million in the year ended December 31, 2023 compared to the year ended December 31, 2022. The increase is primarily attributable to interest earned on higher cash balances held in savings and money market accounts subsequent to the Business Combination.
This was primarily attributable to interest earned on lower cash balances held in savings and money market accounts.
Fo r the year ended December 31, 2022, net cash used in operating activities was $(84.7) million.
Cash Flows Provided by Investing Activities In the year ended December 31, 2024, net cash provided by investing activities was $28.4 million, compared to net cash used by investing activities of $(57.9) million in the year ended December 31, 2023.
Cash Flows For the years ended December 31, 2023 and 2022 The following table provides a summary of our cash flows for the years ended December 31, 2023 and December 31, 2022: Year Ended December 31, Change (In thousands, except for percentages) 2023 2022 2023 vs. 2022 Net cash provided by (used in): Operating activities $ (97,296) $ (84,703) $ (12,593) 15 % Investing activities (57,911) (10,686) (47,225) 442 % Financing activities 148,185 50,545 97,640 N/M Effects of currency translation (404) (178) (226) (127) % Net decrease in cash, cash equivalents, and restricted cash $ (7,426) $ (45,022) Cash Flows Used in Operating Activities For th e year ended December 31, 2023, net cash used in operating activities was $(97.3) million.
The consolidated financial statements for the year ended December 31, 2024 included in this Annual Report do not include any adjustments related to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of this uncertainty Cash Flows The following table provides a summary of our cash flows for the years ended December 31, 2024 and December 31, 2023: 68 Years Ended December 31, (in thousands) 2024 2023 Net cash used in operating activities $ (89,060) $ (97,296) Net cash provided by/(used in) investing activities 28,352 (57,911) Net cash provided by financing activities 30,213 148,185 Effects of currency translation on cash, cash equivalents and restricted cash (52) (404) Net decrease in cash, cash equivalents and restricted cash $ (30,547) $ (7,426) Cash Flows Used in Operating Activities Cash flows used in operating activities decreased $8.2 million, or 8%, in the year ended December 31, 2024 compared to the year ended December 31, 2023.
However, at the time, the Company may not have sufficient funds or be able to obtain financing from third parties to pay such amounts. The Company also may not have sufficient shares authorized to pay the Maturity Consideration in shares.
The outcome of the lawsuit is uncertain, and in the event that the Company does not succeed, the Company may not have sufficient funds or be able to obtain financing from third parties to pay amounts related to the lawsuit. See Note 17 - Commitments and Contingencies in our consolidated financial statements for further information.
We utilized the Black-Scholes option-pricing model, which incorporates management’s assumptions and estimates, to value the preferred stock warrants.
To determine the fair value of the maturity portion, we use the Black-Scholes option pricing model.